ARWR
Price
$38.97
Change
+$0.78 (+2.04%)
Updated
Oct 16 closing price
Capitalization
5.39B
45 days until earnings call
Intraday Buy/Sell Signals
CYTK
Price
$59.01
Change
-$3.79 (-6.04%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
7.05B
14 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ARWR vs CYTK

Header iconARWR vs CYTK Comparison
Open Charts ARWR vs CYTKBanner chart's image
Arrowhead Pharmaceuticals
Price$38.97
Change+$0.78 (+2.04%)
Volume$2.6M
Capitalization5.39B
Cytokinetics
Price$59.01
Change-$3.79 (-6.04%)
Volume$37.37K
Capitalization7.05B
ARWR vs CYTK Comparison Chart in %
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. CYTK commentary
Oct 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and CYTK is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 17, 2025
Stock price -- (ARWR: $38.97 vs. CYTK: $58.96)
Brand notoriety: ARWR: Notable vs. CYTK: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 100% vs. CYTK: 85%
Market capitalization -- ARWR: $5.39B vs. CYTK: $7.05B
ARWR [@Biotechnology] is valued at $5.39B. CYTK’s [@Biotechnology] market capitalization is $7.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $104.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTK is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 2 TA indicator(s) are bullish while CYTK’s TA Score has 3 bullish TA indicator(s).

  • ARWR’s TA Score: 2 bullish, 5 bearish.
  • CYTK’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а +8.07% price change this week, while CYTK (@Biotechnology) price change was -2.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.20%. For the same industry, the average monthly price growth was +16.20%, and the average quarterly price growth was +80.31%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

CYTK is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (-1.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($7.06B) has a higher market cap than ARWR($5.39B). ARWR YTD gains are higher at: 107.287 vs. CYTK (33.503). ARWR has higher annual earnings (EBITDA): -52.51M vs. CYTK (-504.83M). ARWR (900M) and CYTK (858M) have equal amount of cash in the bank . ARWR has less debt than CYTK: ARWR (353M) vs CYTK (858M). ARWR has higher revenues than CYTK: ARWR (573M) vs CYTK (85.7M).
ARWRCYTKARWR / CYTK
Capitalization5.39B7.06B76%
EBITDA-52.51M-504.83M10%
Gain YTD107.28733.503320%
P/E RatioN/AN/A-
Revenue573M85.7M669%
Total Cash900M858M105%
Total Debt353M858M41%
FUNDAMENTALS RATINGS
ARWR vs CYTK: Fundamental Ratings
ARWR
CYTK
OUTLOOK RATING
1..100
7817
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10064
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3539
P/E GROWTH RATING
1..100
21
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARWR's Valuation (100) in the Biotechnology industry is in the same range as CYTK (100). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for ARWR (100). This means that CYTK’s stock grew somewhat faster than ARWR’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as CYTK (39). This means that ARWR’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is in the same range as ARWR (2). This means that CYTK’s stock grew similarly to ARWR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRCYTK
RSI
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
84%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASRCX8.36N/A
N/A
Invesco Global Real Estate Income C
MLPRX4.48N/A
N/A
Invesco SteelPath MLP Income C
ABCAX23.23N/A
N/A
American Beacon The London Co Inc Eq A
COMAX29.24N/A
N/A
DWS Digital Horizons A
CSPCX61.64-0.36
-0.58%
American Funds SMALLCAP World 529C

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with IONS. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
+2.90%
IONS - CYTK
64%
Loosely correlated
+1.43%
MLYS - CYTK
51%
Loosely correlated
+1.31%
ARWR - CYTK
46%
Loosely correlated
+6.20%
NEVPF - CYTK
45%
Loosely correlated
N/A
CRNX - CYTK
44%
Loosely correlated
+0.20%
More